Skip to content
Riskpilot
← Back to search
Sign in
Get full access
IMMUNOPHARMA AS
AS
Active
Org 994924273
Mustads Vei 1A, 0283
Oslo
Activities of advertising agencies
·
NACE 7311
Est. 2010 · 16 years old
16 employees
www.immunopharma.net
Monitor
Share
Norway
/
Companies
/
Activities of advertising agencies
/
IMMUNOPHARMA AS
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
NOK millions
0M
4B
7B
11B
14B
1M
2020
11M
2021
21M
2022
14M
2023
12.2B
2024
EBITDA
NOK millions
5M
-12008M
-24021M
-36034M
-48048M
4M
2020
-16M
-500%
2021
-6M
+63%
2022
-13M
-117%
2023
-38438M
-295577%
2024
Income statement
NOK thousands
Item
2020
2021
2022
2023
2024
Revenue
966
11 478
21 059
14 110
12 205 647
Staff expenses
−0
−10 000
−15 478
−13 428
−15 924 096
EBITDA
3 962
−15 587
−6 486
−12 950
−38 438 075
Depreciation & amort.
−567
−552
−196
−18
−79 194
EBIT
3 394
−16 139
−6 682
−12 968
−38 517 269
Net financials
10 554
−24 949
42 029
−87 367
57 211 333
Profit before tax
13 948
−41 089
35 347
−100 335
18 694 064
Tax
3 648
−3 135
−1 386
9 369
4 970 392
Net profit
10 300
−37 954
36 733
−109 704
13 723 672
Balance sheet
NOK thousands
Item
2020
2021
2022
2023
2024
Total assets
307 897
358 690
367 491
267 015
338 081 366
Equity
162 845
256 166
305 327
195 301
209 024 714
Long-term debt
135 345
41 399
28 078
477
384 564
Short-term debt
9 707
61 125
34 085
71 237
128 672 088
Total debt
145 052
102 524
62 164
71 714
129 056 652
Financial ratios
5-year trend
EBITDA margin
-314.9%
This company
15.8%
Market median
-2093% vs market
2020
2024
Equity ratio
61.8%
This company
38.2%
Market median
+62% vs market
2020
2024
Return on equity
6.6%
This company
18.4%
Market median
-64% vs market
2020
2024
Net profit margin
112.4%
This company
8.1%
Market median
+1288% vs market
2020
2024
Asset turnover
0.04×
This company
1.12×
Market median
-96% vs market
2020
2024
Debt / equity
0.62×
This company
0.62×
Market median
+0% vs market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
View
PDF
More on IMMUNOPHARMA AS
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
